Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes
Fig 2
Western blot analysis on Huh-7 cells following incubation with decreasing concentrations of wild-type PCSK9 (500 nM, 50 nM and 5 nM) or gain-of-function PCSK9 D374Y mutant (20 nM, 2 nM and 0.2 nM) and 200 nM of alirocumab (monoclonal antibody to PCSK9) or isotype control monoclonal antibody for 6 hours.
Lane 1 represents control cells incubated without PCSK9 protein or alirocumab/control Ab. Ab, antibody; LDLR, low-density lipoprotein receptor; PCSK9, proprotein convertase subtilisin/kexin type 9.